resistant Hypertension NKFDOGI
-
Upload
an-nisa-khoirun-ummi -
Category
Documents
-
view
221 -
download
0
Transcript of resistant Hypertension NKFDOGI
-
8/12/2019 resistant Hypertension NKFDOGI
1/37
Lady Davis
Institute
Resistant hypertension
Ernesto L. Schiffrin CM, MD, PhD, FRSC, FRCPC Physician-in-Chief, Sir Mortimer B. Davis-Jewish General Hospital,Canada Research Chair in Hypertension and Vascular Research,
Lady Davis Institute for Medical Research, Vice-Chair, Department of Medicine, McGill University, Montreal, PQ, Canada.
-
8/12/2019 resistant Hypertension NKFDOGI
2/37
Vital signs: prevalence,treatment, and control of HTN United States,1999-2002 and 2005-2008
Center for Disease Control and Prevention (CDC) MMWR Morb Mortal 2011;60:103-108.
-
8/12/2019 resistant Hypertension NKFDOGI
3/37
Prevalence of resistant hypertension in the United States, 2003-2008 (average of 2 out 3 measures by a physician)
Persell SD. Hypertension 2011; 57: 1076-1080.
-
8/12/2019 resistant Hypertension NKFDOGI
4/37
Resistant vs refractory hypertension
Resistant hypertension is hypertension that does respond to adequate doses of 3-4 or more antihypertensive drugs. It represents 10-15% of the general hypertensive
population. Refractory hypertension is defined as BP that
not
remains uncontrolled after 3 visits to a hypertension clinic within a minimum 6-month follow-up period. Secondary causes of hypertension, obesity, diabetes,sleep disordered breathing and excess salt intake oruse of AINS drugs are among some of the findingsassociated with resistant or refractory hypertension.
-
8/12/2019 resistant Hypertension NKFDOGI
5/37
Clinical features of 8295 patients with resistant hypertension classified on the basis of ABPM
Prevalence of resistant hypertension in the Spanish ABPM registry
Resistance defined by BP in office 140/90 mmHg and antihypertensive drugs
3
12.2% of 68,045
After ABPM: 62.5% were
After ABPM :55.9%
true resistant 130/80 mmHg
135/85 mmHg
Selected population
-
8/12/2019 resistant Hypertension NKFDOGI
6/37
Calhoun DA et al. Hypertension 2008
-
8/12/2019 resistant Hypertension NKFDOGI
7/37
-
8/12/2019 resistant Hypertension NKFDOGI
8/37
Calhoun DA et al. Hypertension 2008
-
8/12/2019 resistant Hypertension NKFDOGI
9/37
Calhoun DA et al. Hypertension 2008
-
8/12/2019 resistant Hypertension NKFDOGI
10/37
Endothelial dysfunction in resistant hypertension
Quinaglia T et al. Journal of Human Hypertension doi:10.1038/jhh.2011.43
-
8/12/2019 resistant Hypertension NKFDOGI
11/37
-
8/12/2019 resistant Hypertension NKFDOGI
12/37
Resistant hypertension with or without cerebral microangiopathy
Schmieder RA et al. J Clin Hypertens. 2011;13:582 587.
-
8/12/2019 resistant Hypertension NKFDOGI
13/37
How to approach resistant hypertension
The general treatment approach: 1.adding or titrating diuretic therapy,
2.changing the diuretic class to one appropriate for the patie nts
kidney function,
3.using medications with complementary mechanisms of action,
and
4.adding a mineralocorticoid antagonist to the antihypertensive
drug regimen.
-
8/12/2019 resistant Hypertension NKFDOGI
14/37
How to approach resistant hypertension
1. RAS blocker + diuretic + CCB + MR antagonist with or without a beta-blocker
Thiazide diuretics: chlorthalidone @ 25 mg d, preferred for
most patients.
CKD: loop diuretic, most commonly furosemide at 20 mg to
40 mg twice daily.
Vasodilators, centrally acting antihypertensive agents, and
alpha-adrenergic blockers added if failure to control BP.
2.
3.
4.
-
8/12/2019 resistant Hypertension NKFDOGI
15/37
How to approach resistant HTN Adherence needs to be assessed by asking the
patient about medication use, perceptions about medication efficacy, and presence of adverse effects, if any. Patients must be seen every 4 to 8 weeks,with more frequent visits for patients with
uncontrolled BP.
-
8/12/2019 resistant Hypertension NKFDOGI
16/37
Resistant HTN treatment Use of a MR antagonist in addition to a
diuretic, particularly chlorthalidone, in addition to a full dose of a RAS blocker and a CCB is usually associated with control rates of resistant hypertension >80%.
-
8/12/2019 resistant Hypertension NKFDOGI
17/37
Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)
Vclavk J et al. Hyper tens ion . 2011;57:1069-1075.
-
8/12/2019 resistant Hypertension NKFDOGI
18/37
Spironolactone in Resistant Hypertension
Vclavk J et al. Hypertension . 2011;57:1069-1075.
-
8/12/2019 resistant Hypertension NKFDOGI
19/37
Refractory hypertension
Acelajado MC et al. J Clin Hypert 2012;14:7 12
-
8/12/2019 resistant Hypertension NKFDOGI
20/37
Refractory hypertension
Acelajado MC et al. J Clin Hypert 2012;14:7 12
-
8/12/2019 resistant Hypertension NKFDOGI
21/37
-
8/12/2019 resistant Hypertension NKFDOGI
22/37
Response to MR antagonist
Acelajado MC et al. J Clin Hypert 2012;14:7 12
-
8/12/2019 resistant Hypertension NKFDOGI
23/37
Refractory hypertension: mechanisms No evidence of greater fluid retention in
refractory HTN vs controlled resistant HTN since aldosterone or PRA levels not suppressed Greater role of increased cardiac output and or vascular resistance: enhanced sympathetic drive and or increased peripheral resistance secondary to local or circulating pressor agents?
Acelajado MC et al. J Clin Hypert 2012;14:7 12
BP i h ET i
-
8/12/2019 resistant Hypertension NKFDOGI
24/37
BP response to treatment with ET A antagonist compared to guanfacine
Change in siSBP
Change in ASBP Change in ADBP
Bakris G L et al. Hypertension 2010;56:824-830.
ASBP over 24h
Figure 2. Mean change from baseline in sitting systolic BP over time. Observed values at each time point are displayed.
-
8/12/2019 resistant Hypertension NKFDOGI
25/37
New approaches to refractory HTN Catheter-Based Radiofrequency Renal
Sympathetic Denervation Baroreceptor stimulation
-
8/12/2019 resistant Hypertension NKFDOGI
26/37
l h i d i i i i h
-
8/12/2019 resistant Hypertension NKFDOGI
27/37
Renal sympathetic denervation in patients with treatment- resistant hypertension (The Symplicity HTN-2 Trial): a
randomised controlled trial Simplicity HTN- 2 investigators ( Murray D Esler) Lancet
376;1903-1909 2010:
Objective: Activation of the sympathetic renal system is involved in the pathogenesis of hypertension
RCT in patients wint BP>150 mmHg taking 3 drugs: denervation + Rx or Rx alone
Measured systolic BP at 6 months Procedures: Catheter SYMPLICITY in renal arteries
renal
4-6 low-intensity stimulations on the renal artery BP 178/97 mmHg in patients 57-year old (male=60%) taking
mean of 5.2 drugs (35% more than 5 ) a
-
8/12/2019 resistant Hypertension NKFDOGI
28/37
-
8/12/2019 resistant Hypertension NKFDOGI
29/37
Symplicity HTN-1 Investigators Catheter-Based Renal Sympathetic Denervationfor Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months
153 patients with catheter-based renalsympathetic denervation at 19 centers Hypertension . 2011;57:911-917.
-
8/12/2019 resistant Hypertension NKFDOGI
30/37
BP changes after renal sympathetic denervation over 24-months of follow-up
Krum H. et al. Hypertension . 2011;57:911-917.
-
8/12/2019 resistant Hypertension NKFDOGI
31/37
Randomized controlled clinical trials Simplicity HTN 3 DEPART ReSET MIRT DENER-HTN PRAGUE-15 INSPIRE
Recruiting Y Y Y Y Y Y N
Intervention RDN RDN RDN PVI+RDN RDN RDN RDN
No. patients 530 120 70 150 120 150 230
Catheter Simplicity Simplicity Simplicity THERMOCOOL Simplicity Simplicity TBD
Completion 2013 2014 2012 2012 2014 2013 2016
Country USA Belgium Denmark Russia France Czech Rep. Europe
Renalfunction
mGFR/cys C eGFR/mGFR
Imaging renalarteries
Arteriogr (6)
AngioCT (12, 24, 36)
-
8/12/2019 resistant Hypertension NKFDOGI
32/37
Center requirements for application of RDN in refractory HTN
Modified from Joint UK Societies Consensus on RDN for treatment-resistant HTN
Experience Management of resistant hypertension High volume interventional cardiology/radiology
Protocol Written protocol for work-up, procedure & f/uWritten informed consent and ethics approval
Plans for management of complications Infrastructure High quality CT/MRI
Hemodynamics lab
Multidisciplinary
team
HTN specialists experienced in managing resistant HTN
Interventional cardiologists/radiologists experienced inRDN and nephrologists and vascular surgeons
Transparency Participation in registration program
-
8/12/2019 resistant Hypertension NKFDOGI
33/37
-
8/12/2019 resistant Hypertension NKFDOGI
34/37
Carotid Baroreceptor Stimulation, Sympathetic activity, Baroreflex function and Blood pressure in Hypertensive Patients
Heusser K et al. Hypertension 2010;55:619-626
-
8/12/2019 resistant Hypertension NKFDOGI
35/37
-
8/12/2019 resistant Hypertension NKFDOGI
36/37
Conclusion Diagnosis, including ABPM
Exclude secondary causes
3 drugs (RAS inhibitor, CCB, diuretic) + MR blocker
Adherence to treatment, salt intake
F/u and only then consider invasive treatments
-
8/12/2019 resistant Hypertension NKFDOGI
37/37
Gracias